Pfizer SWOT Pfizer -- A SWOT

PAGES
2
WORDS
679
Cite
Related Topics:

Opportunities

According to the Pfizer press release section of its website, discomfort associated with fibromyaglia, a common chronic pain condition, has been shown to be significantly reduced by a new drug developed by Pfizer called Lyrica, "according to study results presented today at the American Academy of Neurology annual meeting" ("Lyrica Significantly Reduced Pain," 2007, Press Release). Pfizer has also developed a new AIDS drug called Maraviroc, which is likely to considerably improve and extend the life of AIDS patients who take the drug, according to researchers at the University of Pittsburg and Columbia University (Altman & Pollock, 2007).

Threats

Both Merck and Schering-Plough, two of Pfizer's greatest rivals, plan to combine forces and develop a medicine to rival Lipitor. "The planned drug, meant to reduce levels of the harmful type of cholesterol in two ways, could hit the market when Lipitor's patent expires in a few years" ("Merck and Schering-Plough Plan Another Cholesterol Drug," 2007, AP Wire) Merck also plans to develop an AIDS-fighting drug called Raltegravir, similar to Pfizer's new AIDS drug.(Altman &...

...

(28 Feb 2007). "2 New Drugs Offer Options in H.I.V. Fight." The New York Times. Retrieved 16 May 2007 at http://www.nytimes.com/2007/02/28/health/28hiv.html?ei=5070&en=c009b27fab6d02ae&ex=1179460800&pagewanted=print
Berenson, Alex. (10 Apr 2007). "Pfizer Drug for Diabetes Is Lagging." The New York

Times. Retrieved 16 May 2007 at http://www.nytimes.com/2007/04/10/business/10drug.html?ei=5070&en=24b0845a8ddbc0d1&ex=1179460800&adxnnl=1&adxnnlx=1179352594-6dgJ3Hydh0yYFcYeNY+5Fg&pagewanted=print

Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show. (1 May 2007). Pfizer Press Release. Retrieved 16 May 2007 at http://www.pfizer.com

Merck and Schering-Plough Plan Another Cholesterol Drug." (27 Mar 2007) AP Wire. Retrieved 16 May 2007 at http://www.nytimes.com/2007/03/27/business/27drugs.html?ei=5070&en=1d60e4ad92f446ae&ex=1179460800&pagewanted=print

Pfizer.com. (2007). Official Website. Retrieved 16 May 2007 at http://www.pfizer.com/pfizer/main.jsp

Sources Used in Documents:

Works Cited

Altman, Lawrence & Andrew Pollock. (28 Feb 2007). "2 New Drugs Offer Options in H.I.V. Fight." The New York Times. Retrieved 16 May 2007 at http://www.nytimes.com/2007/02/28/health/28hiv.html?ei=5070&en=c009b27fab6d02ae&ex=1179460800&pagewanted=print

Berenson, Alex. (10 Apr 2007). "Pfizer Drug for Diabetes Is Lagging." The New York

Times. Retrieved 16 May 2007 at http://www.nytimes.com/2007/04/10/business/10drug.html?ei=5070&en=24b0845a8ddbc0d1&ex=1179460800&adxnnl=1&adxnnlx=1179352594-6dgJ3Hydh0yYFcYeNY+5Fg&pagewanted=print

Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show. (1 May 2007). Pfizer Press Release. Retrieved 16 May 2007 at http://www.pfizer.com
Merck and Schering-Plough Plan Another Cholesterol Drug." (27 Mar 2007) AP Wire. Retrieved 16 May 2007 at http://www.nytimes.com/2007/03/27/business/27drugs.html?ei=5070&en=1d60e4ad92f446ae&ex=1179460800&pagewanted=print
Pfizer.com. (2007). Official Website. Retrieved 16 May 2007 at http://www.pfizer.com/pfizer/main.jsp


Cite this Document:

"Pfizer SWOT Pfizer -- A" (2007, May 16) Retrieved April 20, 2024, from
https://www.paperdue.com/essay/pfizer-swot-pfizer-a-37676

"Pfizer SWOT Pfizer -- A" 16 May 2007. Web.20 April. 2024. <
https://www.paperdue.com/essay/pfizer-swot-pfizer-a-37676>

"Pfizer SWOT Pfizer -- A", 16 May 2007, Accessed.20 April. 2024,
https://www.paperdue.com/essay/pfizer-swot-pfizer-a-37676

Related Documents

Merck Novartis Merck and Novartis Financial Statements 2012 Balance Sheet • What components of stockholders' equity do each of the companies disclose? Merck & Co. provides a consolidated statement of stockholders equity on their balance sheet. They disclose the number of shares, share types, retained earnings, and some historical data (Merck & Co., 2013). Novartis provides a much more thorough and detailed report of their shareholders equity in their annual report. Not only do they

Corporations have many stakeholders, of which the shareholders are just one group. There are also, for example, creditors, employees, suppliers and customers. In the case of pharmaceutical giants, society at large is also a stakeholder of a sort. The products a company like Merck develops improve the health and well-being of the population at large. Government can be said to be the stakeholder that represents this interest. In the case of

Merck's Medco The acquisition of Medco (by Merck) is a sign of shifts that are taking place in the health care industry. What is happening is there has been an emphasis on providing total health care solutions to consumers. As they are demanding that they have access to: the best services and want to have their different needs combined into one plan. This has lead to changes in the way health

Merck Case Study -- Merck
PAGES 2 WORDS 941

It is different than a criminal action, which involves a breach of duty owed to society at large. It is possible that actions are both tors and crimes; but only the state may prosecute a crime, but any injured party may bring a lawsuit against another as a tort ruling. There are a number of different torts; ranging from assault to negligence, all with foundations in the common law

Merck Tort the Merck Case
PAGES 2 WORDS 580

More than anything else, this case exemplifies a keen sense of legal risk management. The company made enormous profits from the drug while it was selling it; it was highly effective for its on-label purpose and had no known dangerous side effects. After finding that they could be responsible for causing heart problems in patients taking the drug, the company pulled it for ethical reasons and as a means of

Merck and Vioxx -- Research Data How did Merck misuse research data to support their decision for marketing the COX-2 Drug Vioxx? In November of 1998 the pharmaceutical company Merck submitted Vioxx's application to the Food and Drug Administration seeking approval for the COX-2 inhibitor drug, as a treatment for osteoarthritis, on the basis of clinical trials involving 5,400 patients. Merck said the rates of cardiovascular risk were "similar" among patients taking